White Matter Lesions Detected by Magnetic Resonance Imaging After Radiotherapy and High-Dose Chemotherapy in Children With Medulloblastoma or Primitive Neuroectodermal Tumor

White matter lesions (WMLs) have been described as a delayed effect of cranial irradiation in children with brain tumors, or a transient subacute effect characterized by an intralesional or perilesional reaction. We report the occurrence of subacute WMLs detected by magnetic resonance imaging (MRI)...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 22; no. 22; pp. 4551 - 4560
Main Authors FOULADI, Maryam, CHINTAGUMPALA, Murali, KUN, Larry E, MULHERN, Raymond K, GAJJAR, Amar, LANINGHAM, Fred H, ASHLEY, David, KELLIE, Stewart J, LANGSTON, James W, MCCLUGGAGE, Charles W, WOO, Shaio, KOCAK, Mehmet, KRULL, Kevin
Format Journal Article
LanguageEnglish
Published Baltimore, MD American Society of Clinical Oncology 15.11.2004
Lippincott Williams & Wilkins
Subjects
Online AccessGet full text

Cover

Loading…
Abstract White matter lesions (WMLs) have been described as a delayed effect of cranial irradiation in children with brain tumors, or a transient subacute effect characterized by an intralesional or perilesional reaction. We report the occurrence of subacute WMLs detected by magnetic resonance imaging (MRI) in children treated for medulloblastoma or primitive neuroectodermal tumor (PNET) and document the associated clinical, radiologic, and neurocognitive findings. Among 134 patients with medulloblastoma or supratentorial PNET treated prospectively with risk-adjusted craniospinal irradiation and conformal boost to the tumor bed, followed by four high-dose chemotherapy (HDC) cycles with stem-cell rescue, 22 developed WMLs on T1-weighted imaging with and without contrast and/or T2-weighted imaging on MRI. Patients had > or = 12 months of follow-up. Neurocognitive assessments included intelligence quotient (IQ) tests and tests of academic achievement. Twenty-two patients developed WMLs at a median of 7.8 months after starting therapy (range, 1.9 to 13.0 months). Lesions were predominantly in the pons (n = 8) and cerebellum (n = 6). Sixteen patients (73%) had WML resolution at a median of 6.2 months (range, 1.68 to 23.5 months) after onset; two patients developed necrosis and atrophy. Three developed persistent neurologic deficits. Cumulative incidence of WMLs at 1 year was 15% +/- 3%. Patients with WMLs had a significant decline in estimated IQ (-2.5 per year; P = .03) and math (-4.5 per year; P = .003) scores. WMLs in medulloblastoma or PNET patients treated with conformal radiotherapy and HDC are typically transient and asymptomatic, and may mimic early tumor recurrence. A minority of patients with WMLs develop permanent neurologic deficits and imaging changes. Overall, the presence of WMLs is associated with greater neurocognitive decline.
AbstractList White matter lesions (WMLs) have been described as a delayed effect of cranial irradiation in children with brain tumors, or a transient subacute effect characterized by an intralesional or perilesional reaction. We report the occurrence of subacute WMLs detected by magnetic resonance imaging (MRI) in children treated for medulloblastoma or primitive neuroectodermal tumor (PNET) and document the associated clinical, radiologic, and neurocognitive findings. Among 134 patients with medulloblastoma or supratentorial PNET treated prospectively with risk-adjusted craniospinal irradiation and conformal boost to the tumor bed, followed by four high-dose chemotherapy (HDC) cycles with stem-cell rescue, 22 developed WMLs on T1-weighted imaging with and without contrast and/or T2-weighted imaging on MRI. Patients had > or = 12 months of follow-up. Neurocognitive assessments included intelligence quotient (IQ) tests and tests of academic achievement. Twenty-two patients developed WMLs at a median of 7.8 months after starting therapy (range, 1.9 to 13.0 months). Lesions were predominantly in the pons (n = 8) and cerebellum (n = 6). Sixteen patients (73%) had WML resolution at a median of 6.2 months (range, 1.68 to 23.5 months) after onset; two patients developed necrosis and atrophy. Three developed persistent neurologic deficits. Cumulative incidence of WMLs at 1 year was 15% +/- 3%. Patients with WMLs had a significant decline in estimated IQ (-2.5 per year; P = .03) and math (-4.5 per year; P = .003) scores. WMLs in medulloblastoma or PNET patients treated with conformal radiotherapy and HDC are typically transient and asymptomatic, and may mimic early tumor recurrence. A minority of patients with WMLs develop permanent neurologic deficits and imaging changes. Overall, the presence of WMLs is associated with greater neurocognitive decline.
Purpose White matter lesions (WMLs) have been described as a delayed effect of cranial irradiation in children with brain tumors, or a transient subacute effect characterized by an intralesional or perilesional reaction. We report the occurrence of subacute WMLs detected by magnetic resonance imaging (MRI) in children treated for medulloblastoma or primitive neuroectodermal tumor (PNET) and document the associated clinical, radiologic, and neurocognitive findings. Patients and Methods Among 134 patients with medulloblastoma or supratentorial PNET treated prospectively with risk-adjusted craniospinal irradiation and conformal boost to the tumor bed, followed by four high-dose chemotherapy (HDC) cycles with stem-cell rescue, 22 developed WMLs on T1-weighted imaging with and without contrast and/or T2-weighted imaging on MRI. Patients had ≥ 12 months of follow-up. Neurocognitive assessments included intelligence quotient (IQ) tests and tests of academic achievement. Results Twenty-two patients developed WMLs at a median of 7.8 months after starting therapy (range, 1.9 to 13.0 months). Lesions were predominantly in the pons (n = 8) and cerebellum (n = 6). Sixteen patients (73%) had WML resolution at a median of 6.2 months (range, 1.68 to 23.5 months) after onset; two patients developed necrosis and atrophy. Three developed persistent neurologic deficits. Cumulative incidence of WMLs at 1 year was 15% ± 3%. Patients with WMLs had a significant decline in estimated IQ (−2.5 per year; P = .03) and math (−4.5 per year; P = .003) scores. Conclusion WMLs in medulloblastoma or PNET patients treated with conformal radiotherapy and HDC are typically transient and asymptomatic, and may mimic early tumor recurrence. A minority of patients with WMLs develop permanent neurologic deficits and imaging changes. Overall, the presence of WMLs is associated with greater neurocognitive decline.
Author Maryam Fouladi
Charles W. McCluggage
Murali Chintagumpala
David Ashley
Stewart J. Kellie
Amar Gajjar
Mehmet Kocak
Kevin Krull
Fred H. Laningham
Shaio Woo
Larry E. Kun
Raymond K. Mulhern
James W. Langston
Author_xml – sequence: 1
  givenname: Maryam
  surname: FOULADI
  fullname: FOULADI, Maryam
  organization: Children's Hospital at Westmead, and the University of Sydney, Sydney, Australia
– sequence: 2
  givenname: Murali
  surname: CHINTAGUMPALA
  fullname: CHINTAGUMPALA, Murali
  organization: Children's Hospital at Westmead, and the University of Sydney, Sydney, Australia
– sequence: 3
  givenname: Larry E
  surname: KUN
  fullname: KUN, Larry E
  organization: Children's Hospital at Westmead, and the University of Sydney, Sydney, Australia
– sequence: 4
  givenname: Raymond K
  surname: MULHERN
  fullname: MULHERN, Raymond K
  organization: Children's Hospital at Westmead, and the University of Sydney, Sydney, Australia
– sequence: 5
  givenname: Amar
  surname: GAJJAR
  fullname: GAJJAR, Amar
  organization: Children's Hospital at Westmead, and the University of Sydney, Sydney, Australia
– sequence: 6
  givenname: Fred H
  surname: LANINGHAM
  fullname: LANINGHAM, Fred H
  organization: Children's Hospital at Westmead, and the University of Sydney, Sydney, Australia
– sequence: 7
  givenname: David
  surname: ASHLEY
  fullname: ASHLEY, David
  organization: Children's Hospital at Westmead, and the University of Sydney, Sydney, Australia
– sequence: 8
  givenname: Stewart J
  surname: KELLIE
  fullname: KELLIE, Stewart J
  organization: Children's Hospital at Westmead, and the University of Sydney, Sydney, Australia
– sequence: 9
  givenname: James W
  surname: LANGSTON
  fullname: LANGSTON, James W
  organization: Children's Hospital at Westmead, and the University of Sydney, Sydney, Australia
– sequence: 10
  givenname: Charles W
  surname: MCCLUGGAGE
  fullname: MCCLUGGAGE, Charles W
  organization: Children's Hospital at Westmead, and the University of Sydney, Sydney, Australia
– sequence: 11
  givenname: Shaio
  surname: WOO
  fullname: WOO, Shaio
  organization: Children's Hospital at Westmead, and the University of Sydney, Sydney, Australia
– sequence: 12
  givenname: Mehmet
  surname: KOCAK
  fullname: KOCAK, Mehmet
  organization: Children's Hospital at Westmead, and the University of Sydney, Sydney, Australia
– sequence: 13
  givenname: Kevin
  surname: KRULL
  fullname: KRULL, Kevin
  organization: Children's Hospital at Westmead, and the University of Sydney, Sydney, Australia
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16283598$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/15542806$$D View this record in MEDLINE/PubMed
BookMark eNpFkUFrGzEQhUVJaZy0596KLqWndaTVaiUfg9MmKU5TQkp6E1rtyKuwKxlJbvCP6n-sjE0DgkHMe4-Zb87QiQ8eEPpIyZzWhFx8X97PS23mhM0Jl2_QjPJaVEJwfoJmRLC6opL9PkVnKT0TQhvJ-Dt0SjlvaknaGfr7NLgM-E7nDBGvILngE76CDCZDj7tdaa09ZGfwA6TgtTeAbye9dn6NL-3e9KB7F_IAUW92WPse37j1UF2FBHg5wPS_5Xz5u7GP4PGTywO-g347jqEbdcph0jhE_DO6yWX3B_AP2MZQhgg9xEmP-HE7hfgevbV6TPDhWM_Rr29fH5c31er--nZ5uaoM4yJXhnO96IFq2WopiGGia5pWiNqA5aRtbEeopa2UYBhpLKFCMrowmtiuI8QCO0cXh1wTQ0oRrNqUwXTcKUrUHrwq4NUevCJMFfDF8eng2Gy7CfpX_ZF0EXw-CnQyerSxkHTpVdfW5TSLfdCXg24oFF9cBJXK-mOJrdWzCXWtyms4p-wfz_ud2g
CitedBy_id crossref_primary_10_1002_pbc_24954
crossref_primary_10_1016_j_ijrobp_2007_07_2377
crossref_primary_10_1016_j_ijrobp_2015_05_018
crossref_primary_10_1002_cncr_22129
crossref_primary_10_1002_pbc_26619
crossref_primary_10_21682_2311_1267_2020_7_2_126_33
crossref_primary_10_1002_cncr_22761
crossref_primary_10_1016_S1470_2045_17_30030_X
crossref_primary_10_1016_j_ijrobp_2019_08_039
crossref_primary_10_1586_14737140_6_5_709
crossref_primary_10_1093_neuonc_noad186
crossref_primary_10_3389_fncel_2019_00241
crossref_primary_10_1016_j_ijrobp_2014_08_354
crossref_primary_10_1007_s11060_021_03799_3
crossref_primary_10_1016_j_ijrobp_2006_12_030
crossref_primary_10_1016_j_neuropsychologia_2008_08_011
crossref_primary_10_3174_ajnr_A7393
crossref_primary_10_3390_cancers16091716
crossref_primary_10_1007_s00280_016_3161_0
crossref_primary_10_1002_jmri_21364
crossref_primary_10_1200_JCO_2008_18_6437
crossref_primary_10_3389_fonc_2022_874317
crossref_primary_10_1016_j_radonc_2019_05_020
crossref_primary_10_1016_S2173_5107_11_70007_6
crossref_primary_10_1111_ped_14409
crossref_primary_10_1016_j_ijrobp_2011_02_059
crossref_primary_10_1007_s12264_023_01096_9
crossref_primary_10_14338_IJPT_15_00036_1
crossref_primary_10_1111_j_1440_1789_2008_00945_x
crossref_primary_10_1007_s11060_011_0794_z
crossref_primary_10_1007_s00280_008_0859_7
crossref_primary_10_1016_j_jns_2009_06_031
crossref_primary_10_1634_theoncologist_2008_0130
crossref_primary_10_1007_s11060_018_03063_1
crossref_primary_10_1016_j_ijrobp_2017_11_026
crossref_primary_10_1016_j_path_2020_01_004
crossref_primary_10_1007_s00066_013_0408_0
crossref_primary_10_1080_09297049_2023_2172149
crossref_primary_10_1016_j_ijrobp_2007_01_034
crossref_primary_10_1016_j_ijrobp_2015_09_015
crossref_primary_10_1007_s11060_015_1962_3
crossref_primary_10_18632_oncotarget_19553
crossref_primary_10_1002_pbc_25901
crossref_primary_10_1177_2096595820902565
crossref_primary_10_1002_pbc_25946
crossref_primary_10_1080_13854046_2020_1794045
crossref_primary_10_1007_s00401_005_0023_y
crossref_primary_10_1093_nop_npaa002
crossref_primary_10_3389_fonc_2021_573798
crossref_primary_10_1080_13854046_2016_1216070
crossref_primary_10_3171_jns_2005_102_2_0179
crossref_primary_10_1016_j_neuchi_2018_03_002
crossref_primary_10_1080_14737175_2017_1375405
crossref_primary_10_1080_09297049_2021_1885639
crossref_primary_10_1016_j_ijrobp_2008_03_056
crossref_primary_10_1016_j_nicl_2021_102891
crossref_primary_10_1016_S1470_2045_06_70867_1
crossref_primary_10_1080_09553002_2017_1387305
crossref_primary_10_3390_cancers14030837
crossref_primary_10_1634_stemcells_2007_1009
crossref_primary_10_1016_j_ijrobp_2017_11_037
crossref_primary_10_1093_neuonc_nos212
crossref_primary_10_1007_s12253_011_9464_x
crossref_primary_10_1007_s12311_020_01225_4
crossref_primary_10_1016_j_neurad_2022_03_007
crossref_primary_10_1080_14737175_2018_1425617
crossref_primary_10_1093_neuonc_noab301
crossref_primary_10_1016_j_radonc_2016_11_001
crossref_primary_10_1016_S1470_2045_05_70252_7
crossref_primary_10_1186_1748_717X_5_9
crossref_primary_10_3390_bioengineering5030073
crossref_primary_10_1097_RCT_0000000000001481
crossref_primary_10_1016_j_ejpn_2015_07_011
crossref_primary_10_1016_j_neuchi_2008_07_012
crossref_primary_10_1111_1754_9485_12232
crossref_primary_10_3174_ajnr_A3219
crossref_primary_10_1016_j_ijrobp_2019_06_2534
crossref_primary_10_1044_2018_PERS_SIG2_2018_0021
crossref_primary_10_3389_fnimg_2022_845609
crossref_primary_10_1093_neuonc_noac044
crossref_primary_10_1093_neuonc_nor015
crossref_primary_10_1016_j_radonc_2024_110157
crossref_primary_10_1007_s11060_008_9726_y
crossref_primary_10_3390_cancers14235863
crossref_primary_10_26599_BSA_2019_9050008
crossref_primary_10_3389_fpsyg_2018_00703
crossref_primary_10_1016_S1470_2045_06_70872_5
crossref_primary_10_1016_j_rx_2010_11_005
crossref_primary_10_1016_j_ijrobp_2018_01_013
crossref_primary_10_3109_0284186X_2014_957414
crossref_primary_10_1186_s40348_018_0087_0
crossref_primary_10_1002_pbc_20731
crossref_primary_10_1037_0894_4105_20_1_105
crossref_primary_10_1007_s00247_016_3750_4
crossref_primary_10_1016_S1470_2045_08_70125_6
Cites_doi 10.1093/brain/123.5.1041
10.1212/WNL.35.8.1152
10.1177/155005948201300310
10.1037/0735-7044.108.5.848
10.1212/WNL.51.2.433
10.1111/j.1749-6632.2002.tb07578.x
10.1002/(SICI)1096-911X(199706)28:6<387::AID-MPO1>3.0.CO;2-C
10.1002/1097-0142(19951115)76:10<1846::AID-CNCR2820761025>3.0.CO;2-8
10.1007/s00381-001-0526-3
10.1016/S0360-3016(99)00367-3
10.1002/1097-0142(19940915)74:6<1827::AID-CNCR2820740628>3.0.CO;2-Q
10.1212/WNL.59.1.40
10.1002/1097-0142(19921001)70:7<1997::AID-CNCR2820700732>3.0.CO;2-G
10.1002/cncr.11355
10.1016/S0360-3016(99)00366-1
10.1016/0028-3932(96)00001-2
10.1002/1531-8249(199912)46:6<834::AID-ANA5>3.0.CO;2-M
10.1227/00006123-199110000-00025
10.1200/JCO.1992.10.2.249
10.1016/0028-3932(92)90105-U
10.1002/1097-0142(19851115)56:10<2430::AID-CNCR2820561017>3.0.CO;2-3
10.1016/S0730-725X(00)00182-X
10.1093/brain/121.11.2175
10.1002/1097-0142(19860801)58:3<635::AID-CNCR2820580307>3.0.CO;2-X
10.1016/S0360-3016(98)00514-8
10.1016/0360-3016(94)00655-5
10.1016/S0730-725X(98)00014-9
10.1200/JCO.2001.19.8.2302
10.1002/1097-0142(19921201)70:11<2728::AID-CNCR2820701126>3.0.CO;2-7
10.1001/archneur.1996.00550080140022
10.1002/mpo.2950130607
10.1212/WNL.43.8.1536
10.1093/brain/121.4.561
10.1016/S0360-3016(00)00471-5
10.1002/mpo.2950220216
10.1056/NEJM197804132981504
ContentType Journal Article
Copyright 2005 INIST-CNRS
Copyright_xml – notice: 2005 INIST-CNRS
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
DOI 10.1200/JCO.2004.03.058
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
DatabaseTitleList MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1527-7755
EndPage 4560
ExternalDocumentID 10_1200_JCO_2004_03_058
15542806
16283598
jco22_22_4551
Genre Multicenter Study
Research Support, U.S. Gov't, P.H.S
Clinical Trial
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: CA21765
GroupedDBID -
0R
2WC
34G
39C
3O-
4.4
53G
55
5GY
5RE
8F7
8WZ
A6W
AAPEM
AARDX
AAWTL
AAYEP
ABFLS
ABOCM
ACDCL
ACGFS
ADBBV
ADBIT
ADKWQ
AENEX
AFFNX
ALMA_UNASSIGNED_HOLDINGS
ASPBG
AVWKF
AWKKM
AZFZN
BAWUL
CS3
DIK
EBS
EJD
F5P
FD8
FH7
GJ
GX1
H13
HZ
IH2
K-O
KQ8
L7B
LSO
N9A
NTWIH
O9-
OK1
OVD
OWW
P2P
RHI
RUC
SJN
SV3
TWZ
UDS
VH1
WH7
X7M
YCJ
ZA5
ZGI
---
.55
.GJ
08G
08P
08R
0R~
18M
29K
5VS
AAKAS
AAQQT
AAUGY
AAYOK
ACGFO
ADZCM
AEGXH
AI.
AIAGR
C45
D-I
EX3
F9R
FBNNL
FEDTE
HZ~
IPNFZ
IQODW
J5H
MJL
N4W
QTD
R1G
RIG
RLZ
TEORI
TR2
UHU
VVN
WOQ
WOW
YFH
YQY
ABJNI
ACGUR
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
ID FETCH-LOGICAL-c357t-c55a9de1a86a870c37b446772cef5064fb01f1688ec304f0178319ca0fbb00fe3
ISSN 0732-183X
IngestDate Fri Aug 23 03:02:05 EDT 2024
Sat Sep 28 07:44:01 EDT 2024
Sun Oct 22 16:07:56 EDT 2023
Tue Jan 05 20:16:52 EST 2021
IsPeerReviewed true
IsScholarly true
Issue 22
Keywords Human
Antineoplastic agent
Radiotherapy
Nuclear magnetic resonance imaging
White matter
Neuroectodermal tumor
Chemotherapy
Primitive
Cancerology
Treatment
Medulloblastoma
Medical imagery
Lesion
High dose
Child
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c357t-c55a9de1a86a870c37b446772cef5064fb01f1688ec304f0178319ca0fbb00fe3
PMID 15542806
PageCount 10
ParticipantIDs crossref_primary_10_1200_JCO_2004_03_058
pubmed_primary_15542806
pascalfrancis_primary_16283598
highwire_smallpub2_jco22_22_4551
ProviderPackageCode RHI
PublicationCentury 2000
PublicationDate 2004-11-15
PublicationDateYYYYMMDD 2004-11-15
PublicationDate_xml – month: 11
  year: 2004
  text: 2004-11-15
  day: 15
PublicationDecade 2000
PublicationPlace Baltimore, MD
PublicationPlace_xml – name: Baltimore, MD
– name: United States
PublicationTitle Journal of clinical oncology
PublicationTitleAlternate J Clin Oncol
PublicationYear 2004
Publisher American Society of Clinical Oncology
Lippincott Williams & Wilkins
Publisher_xml – name: American Society of Clinical Oncology
– name: Lippincott Williams & Wilkins
References R41
R40
R21
R20
R42
R23
R22
R25
R24
R27
R26
R29
R28
R1
R2
R3
R4
R5
R6
R7
R8
R9
R30
R10
R32
R31
R12
R34
R11
R33
R14
R36
R13
R35
R16
R38
R15
R37
R18
R17
R39
R19
References_xml – ident: R36
  doi: 10.1093/brain/123.5.1041
– ident: R35
  doi: 10.1212/WNL.35.8.1152
– ident: R21
  doi: 10.1177/155005948201300310
– ident: R34
  doi: 10.1037/0735-7044.108.5.848
– ident: R38
  doi: 10.1212/WNL.51.2.433
– ident: R42
  doi: 10.1111/j.1749-6632.2002.tb07578.x
– ident: R3
  doi: 10.1002/(SICI)1096-911X(199706)28:6<387::AID-MPO1>3.0.CO;2-C
– ident: R2
  doi: 10.1002/1097-0142(19951115)76:10<1846::AID-CNCR2820761025>3.0.CO;2-8
– ident: R8
  doi: 10.1007/s00381-001-0526-3
– ident: R30
  doi: 10.1016/S0360-3016(99)00367-3
– ident: R18
  doi: 10.1002/1097-0142(19940915)74:6<1827::AID-CNCR2820740628>3.0.CO;2-Q
– ident: R19
  doi: 10.1212/WNL.59.1.40
– ident: R1
  doi: 10.1002/1097-0142(19921001)70:7<1997::AID-CNCR2820700732>3.0.CO;2-G
– ident: R28
  doi: 10.1002/cncr.11355
– ident: R29
  doi: 10.1016/S0360-3016(99)00366-1
– ident: R32
  doi: 10.1016/0028-3932(96)00001-2
– ident: R26
  doi: 10.1002/1531-8249(199912)46:6<834::AID-ANA5>3.0.CO;2-M
– ident: R22
  doi: 10.1227/00006123-199110000-00025
– ident: R24
  doi: 10.1200/JCO.1992.10.2.249
– ident: R33
  doi: 10.1016/0028-3932(92)90105-U
– ident: R31
– ident: R14
– ident: R37
– ident: R6
  doi: 10.1002/1097-0142(19851115)56:10<2430::AID-CNCR2820561017>3.0.CO;2-3
– ident: R27
  doi: 10.1016/S0730-725X(00)00182-X
– ident: R39
  doi: 10.1093/brain/121.11.2175
– ident: R10
  doi: 10.1002/1097-0142(19860801)58:3<635::AID-CNCR2820580307>3.0.CO;2-X
– ident: R12
  doi: 10.1016/S0360-3016(98)00514-8
– ident: R13
  doi: 10.1016/0360-3016(94)00655-5
– ident: R25
  doi: 10.1016/S0730-725X(98)00014-9
– ident: R16
  doi: 10.1200/JCO.2001.19.8.2302
– ident: R5
  doi: 10.1002/1097-0142(19921201)70:11<2728::AID-CNCR2820701126>3.0.CO;2-7
– ident: R9
  doi: 10.1001/archneur.1996.00550080140022
– ident: R7
  doi: 10.1002/mpo.2950130607
– ident: R40
  doi: 10.1212/WNL.43.8.1536
– ident: R41
  doi: 10.1093/brain/121.4.561
– ident: R11
– ident: R20
  doi: 10.1016/S0360-3016(00)00471-5
– ident: R23
  doi: 10.1002/mpo.2950220216
– ident: R4
  doi: 10.1056/NEJM197804132981504
– ident: R15
– ident: R17
SSID ssj0014835
Score 2.2143626
Snippet White matter lesions (WMLs) have been described as a delayed effect of cranial irradiation in children with brain tumors, or a transient subacute effect...
Purpose White matter lesions (WMLs) have been described as a delayed effect of cranial irradiation in children with brain tumors, or a transient subacute...
SourceID crossref
pubmed
pascalfrancis
highwire
SourceType Aggregation Database
Index Database
Publisher
StartPage 4551
SubjectTerms Adolescent
Atrophy
Biological and medical sciences
Brain - pathology
Brain Neoplasms - radiotherapy
Case-Control Studies
Cerebellar Neoplasms - radiotherapy
Child
Cognition Disorders - etiology
Cranial Irradiation - adverse effects
Female
Humans
Incidence
Magnetic Resonance Imaging
Male
Medical sciences
Medulloblastoma
Necrosis
Neuroectodermal Tumors, Primitive - radiotherapy
Neurology
Prospective Studies
Radiation Injuries - epidemiology
Radiation Injuries - pathology
Radiotherapy, Conformal
Risk Factors
Tumors
Tumors of the nervous system. Phacomatoses
Title White Matter Lesions Detected by Magnetic Resonance Imaging After Radiotherapy and High-Dose Chemotherapy in Children With Medulloblastoma or Primitive Neuroectodermal Tumor
URI http://jco.ascopubs.org/content/22/22/4551.abstract
https://www.ncbi.nlm.nih.gov/pubmed/15542806
Volume 22
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1tb9MwELa2ISG-IBgDyst0H9CE1HWkzkvTj1PHKGihE-pEv0WOk2xFbTK1KVL5T_xH7uw4SQuIF6mK2lRynd49d2f77jnGXkVp4kcJRm5OatsdpysRUlY_xkBOeFI4GJMK2tAPPnrDK-fDxJ3s7B40spZWRXQiv_2yruR_pIr3UK5UJfsPkq0GxRv4HuWLV5QwXv9Kxqq7XTtQFJnti2SpktrOEjoX0IFlIK4zqlJUu_SZqg54P9d9iU5Vc_BPIp6WNViaiInyPjpnlMROVALVV1QbaMq-P9PWbYAuajbLIwy-i3wuKK39kjqEqUwkxfhBxwEx2f1Ze7ya54vfhMFVaWaeyY0t_kAs1mJOfZ9mOMmGYuDKQbX9LsQ16qKYVY7lnHLphyftC0GbPTdiXm_Df53GqIk35hTbbHM4VO-nCz0blQVk8spkVkpWMRMcNSeobWfP5h20VhPt5krbznuog5oV2Bh_zhtKXn7QptxxNRPuTz6G6_bZg5HaXVAUuZp9vqFxt3OlchSs0dF17WxNgsGWD64yI7_InPMQX_Tzu-wOR_tJhvvdpMpcwgWs7htrnrFkrMLZvNmalWo6paewGXcZLmxKBRZL_A9T3cZla3GlgqzxA3a_VAs41ar-kO0k2T67G5T5H_vs6FIzra-PYVwXDi6P4Qguaw729SP2XUEDNDSghAYYaEC0BgMNqKABJTRAQQOa0ACEBlTQgCY0YJqBgQYQNGALGpAvoIIGbEEDFDQO2NX52_Fg2Ck7k3Sk7faKjnRd0Y-TrvA9gQ5P2r3IwYijx2WSEgNkGlndtOv5fiJty0nR6_no6qSw0gjdXJrYj9lelmfJUwZp6nuelE7sxrYjXS6k3-eWiPsyjuzIky322sgtvNUENCEt3DmdQg9G1EbWCS07RGm3GBi5hkt8hBmKkocbGtVihxvyrof0iHixj2M80QpQf1Mq0LM_j_6c3auh-4LtFYtV8hJj9iI6VBr8A9VO9Bk
link.rule.ids 315,783,787,27936,27937
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=White+Matter+Lesions+Detected+by+Magnetic+Resonance+Imaging+After+Radiotherapy+and+High-Dose+Chemotherapy+in+Children+With+Medulloblastoma+or+Primitive+Neuroectodermal+Tumor&rft.jtitle=Journal+of+clinical+oncology&rft.au=Maryam+Fouladi&rft.au=Murali+Chintagumpala&rft.au=Fred+H.+Laningham&rft.au=David+Ashley&rft.date=2004-11-15&rft.pub=American+Society+of+Clinical+Oncology&rft.issn=0732-183X&rft.eissn=1527-7755&rft.volume=22&rft.issue=22&rft.spage=4551&rft_id=info:doi/10.1200%2FJCO.2004.03.058&rft_id=info%3Apmid%2F15542806&rft.externalDBID=n%2Fa&rft.externalDocID=jco22_22_4551
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon